MacroGenics Priced, Nasdaq: MGNX
Developing targeted therapeutics for cancer and autoimmune diseases.
Industry: Health Care
First Day Return: +56.2%
MGNX
Developing targeted therapeutics for cancer and autoimmune diseases.
| IPO Data | |
|---|---|
| IPO Date | 10/09/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $80 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Rockville, MD, United States |
| Founded | 2000 |
| Employees at IPO | 156 |
| Website www.macrogenics.com | |
IPO News for MacroGenics
MacroGenics (MGNX) Performance
